Citius Oncology (CTOR) Non-Current Assets (2022 - 2026)

Citius Oncology's Non-Current Assets history runs 5 years deep, the most recent figure standing at $71.3 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 2.89% year-over-year to $71.3 million; the TTM figure through Mar 2026 stood at $290.9 million (up 8.0% YoY), while the FY2025 annual figure was $73.4 million, changed 0.0% from the prior year.
• Non-Current Assets was $71.3 million for Q1 2026 at Citius Oncology, down from $72.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $73.4 million in Q3 2024 to a low of $40.0 million in Q3 2023.
• Historically, Non-Current Assets has averaged $66.2 million across 5 years, with a median of $71.9 million in 2023.
• Biggest YoY gain for Non-Current Assets was 83.5% in 2024; the steepest drop was 29.16% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $67.8 million in 2022, then grew by 7.01% to $72.6 million in 2023, then grew by 1.15% to $73.4 million in 2024, then dropped by 0.78% to $72.8 million in 2025, then declined by 2.13% to $71.3 million in 2026.
• The last three Non-Current Assets figures came in at $71.3 million (Q1 2026), $72.8 million (Q4 2025), and $73.4 million (Q3 2025), per Business Quant data.